Forte Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 9
- Market Cap
- -
- Website
- http://www.fortebiorx.com
- Introduction
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner in 2017 and is headquartered in Dallas, TX.
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FB102 IN ADULT WITH CELIAC DISEASE
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Forte Biosciences, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06982963
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo
- First Posted Date
- 2025-04-02
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Forte Biosciences, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT06905873
- Locations
- 🇦🇺
Skin & Cancer Foundation Australia - The Skin Hospital, Darlinghurst, New South Wales, Australia
🇦🇺Novatrials, Kotara, New South Wales, Australia
🇦🇺Cornerstone Dermatology, Coorparoo, Queensland, Australia
Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study
- Conditions
- Atopic Dermatitis
- Interventions
- Biological: FB-401
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Forte Biosciences, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04936113
- Locations
- 🇺🇸
Center for Dermatology Clinical Research, Inc., Fremont, California, United States
🇺🇸Multi-Specialty Research Associates, Inc., Lake City, Florida, United States
🇺🇸Cyn3rgy Research, Gresham, Oregon, United States
Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Biological: PlaceboBiological: FB-401
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Forte Biosciences, Inc.
- Target Recruit Count
- 154
- Registration Number
- NCT04504279
- Locations
- 🇺🇸
Minnesota Clinical Study Center, New Brighton, Minnesota, United States
🇺🇸Midwest Children's Health Research Institute, Lincoln, Nebraska, United States
🇺🇸First OC Dermatology, Fountain Valley, California, United States